Abbott Prism Assays, Spectrum Of Product Launches Stalled By QSR Finding
This article was originally published in The Gray Sheet
Executive Summary
Approval of Abbott Laboratories' Prism hepatitis B core antibody and HIV-1/2 assays likely will be delayed by FDA's finding that Abbott's Lake County, Illinois diagnostic manufacturing facility still does not comply with quality system regulations, the firm said